7 Reasons Why Low Float NYSE American Profile (NNVC) Just Topped My High-Alert Watchlist

*Sponsored

February 11th

Greetings, Friend!

It's been a few days, so let me get you all caught up.

My last profile, an under-the-radar Nasdaq idea, caught the breakout bug in the short term.

Surging from a previous night's after-hours close of $6.86+ on 2/6, that profile ballooned to a high of $8.86 one day later.

Popping almost $2.00, the run resulted in a blast of approx. 29%.

Solid, but let's turn our focus to something else bubbling with breakout potential!

This NYSE American profile is popping up on my radar for 2 immediate reasons:

#1. This is a low float profile with fewer than 14Mn shares in its float, which means volatility potential could be significant.

Could that be part of the reason as to why this profile was able to complete a 250% move during the past 12 month period?

#2. A game-changing February press release has somehow stayed off Wall Street's radar, but the details inside are eye-opening. In fact, the catalyst potential talked about in that PR could be monumental for the company.

As this company powers forward in 2025 and beyond, it may just be a matter of time until they become a household name as global health uncertainties could propel their game-changing work into the spotlight.

Hitting #1 on my watchlist this week, it may be time to consider this breakout idea for your radar: NanoViricides, Inc. (NYSE American: NNVC).

NanoViricides, Inc. is a global leader in the development of nanomedicine drugs.

Their unique nanoviricide® platform technology defines a novel mechanism enabling first-in class drugs against vir-uses.

A nanoviricide is designed to specifically attack enveloped vir-us particles, on the same sites that they use to bind to cells, and dismantle them, blocking reinfection cycle, going beyond what antibodies and immunotherapeutics do.

It can also be designed to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity.

The company's unique biomimetic approach enables creation of drugs that a vir-us would be highly unlikely to escape due to mutations.

NanoViricides is one of the few biopharma companies with its own multi-kilogram-scale c-GMP capable manufacturing facility for the drug substance as well as drug product.

This facility is fully owned by the Company with no mortgage and is a major asset.

This flexible, multi-product pilot plant can supply drug product for all of their programs through human clinical trials.

Their cGMP manufacturing ability enables substantial time and cost savings in their drug development programs.

Further, it is capable of production for initial marketing, enabling early revenues upon drug approval, of about $100Mn~$500Mn per year.

Company Sources: Presentation. Website.

As for why someone might want to pay attention to NanoViricides, Inc. (NYSE American: NNVC) right now, here's 7 immediate reasons...

#1. Low float: With a float of approximately 13.97Mn shares, volatility potential could be significant on a daily basis.

#2. NanoViricides Drug Can Fight Bird Flu Pan-dem-ic; H-5-N-1 Vi-rus Cannot Escape: Company president, Anil R. Diwan, Ph.D., said:

"We believe that the new administration will focus on rapid development and acquisition of broad-spectrum therapeutic drugs like NV-387 that the v-irus cannot escape, for the Nation's arsenal of antiviral weaponry, in order to prepare for not just a potential bird flu pan-dem-ic in humans but also potential spread of M-P-ox outside of the African region, and potential Sm-all-pox bi-oterr-orism, all at the same time, with a single drug capable of fighting all of these fights, thus saving Bn's of dollars to the American taxpayer, instead of the failed strategy of chasing vi-rus-es by continuing to develop new multi-Bn-dollar vaccines every few months that was adopted by the Biden administration in response to the CVD pan-dem-ic."

#3. Innovative technology: Their nanoviricide technology could potentially offer a new approach to treating viral infections.

A nanoviricide is created by chemically attaching a vir-us-binding ligand, derived from the binding site of the vir-us on its cell surface receptor, to a nanomicelle flexible polymer. This binding site does not change significantly when a vir-us mutates.

Tailor-made design and selection of (1) the vir-us-binding ligand; and (2) the backbone "nanomicelle," separately, allows the company to rapidly optimize drug candidates (a) against a number of vir-uses, (b) for desired pharmacokinetic characteristics (e.g. sustained effect), and (c) for different routes of administration. This versatility is unmatched in the industry.

#4. Broad application: Their platform could potentially be adapted to target various vir-uses, which might be particularly relevant in a post-CV19 world.

#5. Potential market: If successful, their products could address significant unmet medical needs in antiviral treatments.

#6. NanoViricides Engages CRO for Phase II Clinical Trial: Company president, Anil R. Diwan, Ph.D., shared:

"NV-387, our broad-spectrum antiviral drug is poised to cause a revolution in treatment of viral diseases, just as antibiotics revolutionized the treatment of bacterial diseases. Our regulatory development strategy for this drug is now further advancing into a Phase II clinical trial stage."

#7. Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals: President Diwan also shared:

NV-387 stands apart in the field of antiviral countermeasures in that escape of vir-us even as it evolves is highly unlikely. This is because (i) NV-387 mimics the essential host-side feature that the vir-us requires for causing infection, and (ii) the activity spectrum of NV-387 is so broad, encompassing not just a type of vir-us, but across many different types of vir-uses, that any small changes in a vir-us would be unlikely to enable the vir-us to escape NV-387.

-----

Coverage is officially reinitiated on NanoViricides, Inc. (NYSE American: NNVC). If there are any updates necessary, I'll have them out to you quickly.

Talk again shortly.

All the best,

Dane James

Editor Market Pulse Today

(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)

*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, a single member limited liability company. Data is provided from third-party sources and MarketPulseToday is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.

Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired by TD Media LLC for a period beginning on 02/04/2025 and ending on 02/05/2025 to publicly disseminate information about (NNVC:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid two thousand five hundred USD (“Funds”) to disseminate information about (NNVC:US) via digital communications.

Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired by TD Media LLC for a period beginning on 02/11/2025 and ending on 02/12/2025 to publicly disseminate information about (NNVC:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid five thousand USD (“Funds”) to disseminate information about (NNVC:US) via digital communications. These Funds were part of the funds that TD Media LLC received from a third party who did receive the funds from the issuer and does not own st-ock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices.

Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (NNVC:US).

Please see important disclosure information here: https://marketpulsetoday.com/disclosure/nnvc/#details

7 Reasons Why Low Float NYSE American Profile (NNVC) Just Topped My High-Alert Watchlist

0 Response to "7 Reasons Why Low Float NYSE American Profile (NNVC) Just Topped My High-Alert Watchlist"

Post a Comment